All Posts By

Motif

Motif Bio Acquires Late Stage Antibiotic and Announces Pre-IPO Financing

By Press Releases
Amphion Innovations, a developer of medical, life science, and technology businesses, is pleased to announce that Partner Company, Motif BioSciences Inc. ("Motif"), has entered into an agreement to merge with a private company that holds the intellectual property and world-wide rights to a clinical stage antibiotic designed to be effective against MRSA and multi-drug resistant bacteria (the "Acquisition"). Motif plans to start Phase III trials this year in two serious hospital-acquired infections. Completion of the Acquisition is conditional inter-alia upon Motif completing an IPO before 31 March 2015. Motif is a US-based drug discovery and development company focused on developing solutions for the antibiotic crisis. As of 31 December 2013, Amphion owned 32% of Motif. Amphion is also pleased to...
Read More